We were the first lupus organization in the U.S. to support stromal cell research. In partnership with the National Institute of Allergy and Infectious Diseases, we committed nearly $4 million over ...
NEW YORK, Jan. 16, 2025 /PRNewswire/ -- The Food and Drug Administration (FDA) approved the first mesenchymal stromal cell (MSC) therapy, RYONCIL®, indicated for steroid-refractory acute graft ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback